Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Sales and Divestitures (2022 - 2025)

Abeona Therapeutics has reported Gains from Sales and Divestitures over the past 4 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $1.5 million for Q4 2025, up 44.88% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 44.88% YoY), and the annual figure for FY2025 was $1.5 million, up 44.88%.
  • Gains from Sales and Divestitures for Q4 2025 was $1.5 million at Abeona Therapeutics, up from $1.4 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for ABEO hit a ceiling of $1.5 million in Q4 2025 and a floor of $27526.0 in Q4 2022.
  • Median Gains from Sales and Divestitures over the past 4 years was $659824.0 (2024), compared with a mean of $657008.5.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 882.89% in 2023 and later tumbled 38.84% in 2025.
  • Abeona Therapeutics' Gains from Sales and Divestitures stood at $27526.0 in 2022, then surged by 882.89% to $270550.0 in 2023, then skyrocketed by 273.05% to $1.0 million in 2024, then skyrocketed by 44.88% to $1.5 million in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $1.5 million (Q4 2025), $1.4 million (Q3 2025), and $500780.0 (Q2 2025) per Business Quant data.